2020 ASCO Virtual Direct™ Highlights

 

Lung
24:44

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on EGFR+ NSCLC: Adjuvant Gefitinib, Adjuvant Osimertinib, Bevacizumab + Erlotinib Final Survival Analysis

FEATURING Shayma Kazmi
  • 94 views
  • September 22, 2020
09:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IO in Advanced NSCLC: Nivo/Ipi + 2 Cycles of Chemo vs. 4 Cycles of Chemo - Did OS Improve?

FEATURING Shayma Kazmi
  • 97 views
  • September 22, 2020
08:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ NSCLC: Did Trastuzumab Deruxtecan Demonstrate Favorable Clinical Activity?

FEATURING Shayma Kazmi
  • 390 views
  • September 22, 2020
  • 2
08:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on SCLC: Can a Higher TRT-Dose Prolong Survival in LS-SCLC? Is IP Superior to EP in RFS for Patients With Completely Resected HGNEC?

FEATURING Sandip Patel
  • 201 views
  • August 24, 2020
07:39

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Localized NSCLC: Does the Addition of Pembro to CCRT Increase Antitumor Activity? Gefitinib vs. Adjuvant Chemotherapy - Does the Duration of Therapy Matter in the Curative Setting?

FEATURING Sandip Patel
  • 231 views
  • August 7, 2020
  • 1
06:39

2020 ASCO Virtual Direct™ Highlights

Adjuvant Therapy in Resectable NSCLC: What Does ADAURA Data Suggest on Osimertinib in EGFR+ Disease?

FEATURING Sandip Patel
  • 161 views
  • August 24, 2020
  • 1